Literature DB >> 4734502

Treatment of polymyositis with immunosuppressive drugs.

D C Haas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4734502     DOI: 10.1212/wnl.23.1.55

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

1.  Treatment of dermatomyositis in childhood.

Authors:  V Dubowitz
Journal:  Arch Dis Child       Date:  1976-07       Impact factor: 3.791

Review 2.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  Indications for intravenous gammaglobulin therapy in inflammatory myopathies.

Authors:  P Cherin; S Herson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 4.  Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.

Authors:  Theonymfi Doudouliaki; Charalampia Papadopoulou; Claire T Deakin
Journal:  Curr Rheumatol Rep       Date:  2021-03-08       Impact factor: 4.592

Review 5.  Clinical use of immunosuppressive drugs: part I.

Authors:  N L Gerber; A D Steinberg
Journal:  Drugs       Date:  1976       Impact factor: 9.546

6.  Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases.

Authors:  P Hollingworth; A de Vere Tyndall; B M Ansell; T Platts-Mills; J M Gumpel; J Mertin; D S Smith; A M Denman
Journal:  Ann Rheum Dis       Date:  1982-12       Impact factor: 19.103

Review 7.  Experimental autoallergic myositis, polymyositis and myasthenia gravis. Autoimmune muscle disease associated with immunodeficiency and neoplasia.

Authors:  R L Dawkins
Journal:  Clin Exp Immunol       Date:  1975-08       Impact factor: 4.330

8.  Dermatomyositis: observations on the use of immunosuppressive therapy and review of literature. Cairo--Glasgow study group.

Authors:  A El-Ghobarey; G Balint; K de Ceulaer; W C Dick; W W Buchanan; T Hadidi; T A Hassan
Journal:  Postgrad Med J       Date:  1978-08       Impact factor: 2.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.